All News
#OP0205 #EULAR2026: 🌞SUNSTAR head-to-head trial compared SC TOC vs Abatacept after failure of 1-2 b/tsDMARDs in RA. Primary CDAI endpoint was not met, but composite response and treatment persistence favoured tocilizumab. @RheumNow https://t.co/UepvKcbiNJ
Mrinalini Dey DrMiniDey ( View Tweet)
Effect of IL-17i on metabolic profile and CV safety in PsA/axSpA
169 pts 12mo
-IL-17i no MACE reported
-CRP reduced 4.8 → 2.9 mg/L, p<0.001
-79% systemic inflammatory response
-Lipids stable (LDL, TG, TC)
12mo follow up is probably too short though
#POS0375 #EULAR2026 https://t.co/u6cvB5YYGq
Aurelie Najm AurelieRheumo ( View Tweet)
#OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred oral JAKi over SC TNFi (55% vs 45%)
Importantly, own choice led to higher treatment satisfaction, better drug survival & fewer adverse events. @RheumNow #EULARBest https://t.co/iI1n2OGzqY
Mrinalini Dey DrMiniDey ( View Tweet)
Prospective study of RVZ immunogenicity = heterogeneous cellular immunity across RMDs
12mo 150 pts
-CD4+ gE-T-cell response peaks mo 3
-Response seen in axSpA + GCA, but not RA
-25% of patients no CMI increase after vaccination
Consistent w/other vaccine cellular imm profiles https://t.co/yvDLSHh4Bj
Aurelie Najm AurelieRheumo ( View Tweet)
#OP0203 #EULAR2026: low-dose blinatumomab in multidrug-resistant RA introduced the intriguing concept of “immune dimming”, transient B-cell depletion that appeared to restore responsiveness to previously failed DMARDs, JAK inhibitors and TNFi in several patients. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Frailty as a long term outcome in RA
Higher frailty in RA vs ctrls HR 1.76 in 910 matched pairs.
-10y: 30.6% vs 19.1%
-20y: 53.8% vs 35.3%
-Stronger in recent RA (HR 2.38)
Driven by age, smoking, comorbidity, steroids/biologics not RF/CCP.
Preventive interventions needed https://t.co/pcJrE73G5O
Aurelie Najm AurelieRheumo ( View Tweet)
TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials
8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis
Developed via multistage consensus process
Higher pt enrollment potential?
POS1068 @RheumNow #EULAR2026 https://t.co/W614xZV7TX
sheila RHEUMarampa ( View Tweet)
Catching up on #EULAR2026 “Advanced management in RA” session: #OP0202 reported positive phase 2b RENOIR data for rosnilimab, a selective pathogenic T-cell depleter, with significant improvements in DAS28-CRP, ACR responses and CDAI LDA vs placebo in RA. @RheumNow https://t.co/IKKtakxpya
Mrinalini Dey DrMiniDey ( View Tweet)
Machine learning identifies a “vulnerable” phenotype in older RA patients n=275
-51% “vulnerable”
-Worse grip strength, gait speed & SARC-F
-Higher disability (HAQ 1.56 vs 0.64)
-More fatigue, poorer QoL
-Higher DAS28 despite greater biologic exposure
Suggests we should assess https://t.co/bv1FbTxGKR
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow
https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Depression at RA diagnosis did not predict short-term CV events in a nationwide early RA cohort
-17,669 early RA pts
-7.3% BL depression
-Median follow-up 1.2 years
-No association w/ CV hospitalisation after adjustment (sHR 1.05)
Reassuring short-term data, longer follow-up https://t.co/XmMVGY1VlI
Aurelie Najm AurelieRheumo ( View Tweet)
How many ‘cars’ are there?
crowded #CAR-T ‘driving’ innovation at
#EULAR2026
>90 abstracts w CAR-T in title
Lessons learned
Maybe #immune #reset is not always the goal
➡️vs ’#immune #dimming
How long are effects?
safety looks good
PT selection is key
Early, no damage
@RheumNow https://t.co/6jii5MBJcJ
Links:
Janet Pope Janetbirdope ( View Tweet)
One of the highlights of #EULAR2026 for me:
♀️The "This Is a Woman's World" session
I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬
https://t.co/3jwJIegGg4 via @YouTube
@ArLARheumatolog https://t.co/Azvkl2sjdu
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Failure to achieve early remission RA asso w/ non-inflammatory pain
NORD-STAR 526 early RA pts)
no remission at 24 wks increased risk of 48wk
• unacceptable pain (OR ~6)
• refractory pain (OR ~6)
• fibromyalgic RA (OR ~16)
Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw
Aurelie Najm AurelieRheumo ( View Tweet)
Even with tight T2T, ARCTIC 10yr follow-up (n=170) show 9% had RA-ILD on HRCT, plus another 19% with non-specific interstitial findings. Male sex and older age were risk factors. Seropositivity was not. Vigilance remains essential. @RheumNow #EULAR2026 POS1270
Jiha Lee JihaRheum ( View Tweet)
#EULAR2026 Recommendations: Vasculitis
-Confirm diagnosis with imaging and biopsy
- Start GC early but with taper plan
- For major flare again confirm dx and restart GC
- Consider IL-6 or UPA
- MTX may be option if biologics not available
@RheumNow https://t.co/DqLZtW630y
Jiha Lee JihaRheum ( View Tweet)
#EULAR2026 POS1355 A cohort study in Japan identified 5-score predictors of GC-free remission in #lupusnephritis: HCQ, pulsed IV GC, Chronicity index=0, =>75% UPCR reduction by 6mo,& 12 mths CRR. Data cutoff 2024. Interested to see impact of current Combo tx from outset @RheumNow https://t.co/qmpgyEyOOV
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Core definitions when understanding vaccination.
@RheumNow #EULAR2026 https://t.co/wD0iTDxMEx
sheila RHEUMarampa ( View Tweet)
RheumNow’s expanded coverage of #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
Dr. John Cush RheumNow ( View Tweet)
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?
Over 70% of patients with psoriatic arthritis (PsA) struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response.
https://t.co/pAIXkdazci https://t.co/vQTn3BWv2r
Dr. John Cush RheumNow ( View Tweet)
